In the past decade substantial progress has been made in the treatment of adult ALL (acute lymphoblastic leukemia). With current intensive chemotherapy protocols 30-40% of patients can be cured. The further development of diagnostic facilities and retrospective analysis of outcome of patients have shown that ALL is not a homogenous disease. Diagnosis by morphological, immunological, cytogenetical, and molecular biological methods is a prerequisite for stratification in risk groups. These groups have a different clinical course and prognosis and require specific therapy approaches. Patients with T-ALL and/or mediastinal tumor with CR (complete remission) rates of 80-85% and long-term survival of 40-50% are now a facorable prognostic subgroup. Prognosis of B-ALL patients has been improved substantially by the use of specific therapy concepts. 50-60% of patients can be probably cured. The majority of ALL patients have B-precursor ALL, which can be stratified in high- and low-risk patients by the use of risk factors (time to CR, WBC, Philadelphia (Ph’) chromosome, and bcr-abl rearrangement). Therapy results in this group stagnated in the past years at CR rates of 75-85% and survival rates of about 30%. The main reason is the poor results in the subgroup of Ph’/bcr-abl-positive ALL (20-25% of adult ALL patients) that could not be improved by conventional therapy approaches. Despite an increase in CR rates to 70% long-term survival is still between 10 and 15%. Elderly ALL patients with increased therapy-related toxi-city and mortality are also at high risk of relapse or death. The adult ALL Study Group (GMALL) is currently investigating the possibilities for further improvements by the use of risk-adapted therapy regimens, intensified chemotherapy and BMT in high-risk patients. Further progress might be made by the use of biologic response modifiers, growth factors, better supportive care, and the control of minimal residual disease and multidrug resistance.

Keywords:
Acute lymphoblastic leukemia (ALL), Chemotherapy, Prognostic factors
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.